| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2025-05-29 18:10:10 UTC |
|---|
| HMDB ID | HMDB0000684 |
|---|
| Secondary Accession Numbers | - HMDB0000183
- HMDB00183
- HMDB00684
|
|---|
| Metabolite Identification |
|---|
| Common Name | Kynurenine |
|---|
| Description | L-Kynurenine, which is also known as Kynurenine or 3-Anthraniloylalanine, belongs to the class of compounds known as alkyl-phenylketones. Alkyl-phenylketones are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group. Kynurenine is a metabolite of the amino acid L-tryptophan and is used in the production of niacin. Specifically, kynurenine is synthesized by the enzyme tryptophan dioxygenase, which is made primarily but not exclusively in the liver. Kynurenine is also synthesized by indoleamine 2,3-dioxygenase (IDO), which is found in many tissues and is often overexpressed in response to immune activation. Kynurenine and its other tryptophan breakdown products (Trp catabolites) carry out a wide range of biological functions, including dilating blood vessels during inflammation (PMID: 20190767 ) and regulating the immune response (PMID: 21041655 ). Kynurenine is the precursor to the neuroprotective agent known as kynurenic acid. Kynurenine is also the precursor to the neurotoxic agent quinolinic acid. Dysregulation in the balance between these two kynurenine derivatives can be observable in many disorders such as stroke, epilepsy, multiple sclerosis, and amyotrophic lateral sclerosis. Blood levels of kynurenine are reduced in people with bipolar disorder (PMID: 33077852 ) and schizophrenia (PMID: 21727251 ). On the other hand, kynurenine production is increased in Alzheimer's disease (PMID: 16008823 ). and cardiovascular disease (PMID: 12814390 ), where its metabolites are associated with cognitive deficits (PMID: 20639188 ) and depressive symptoms. Kynurenine and its precursor (tryptophan) also play important roles in regulating inflammation and the immune responses to infectious organisms. Reduced levels of tryptophan in the blood are typically seen when individuals are fighting chronic infections, suffering from traumatic injuries (burns or wounds) or experiencing sepsis (PMID: 26309411 ). Tryptophan is mainly catabolized to kynurenine by the enzyme known as indoleamine-2,3-dioxygenase (IDO) which is induced by interferon gamma (IFN-gamma or IFNG). Kynurenine activates the aryl hydrocarbon receptor (AhR), which plays a key role immune suppression. The role of IDO is to effectively deplete tryptophan levels to starve infectious organisms (bacteria and parasites), thereby killing them or slowing their growth. On the other hand, the AhR activation by kynurenine leads to a state of immunosuppression and is intended to serve as a brake on the immune response to the infectious organisms (overexpression of IFNG and IL-1B). Unfortunately, tryptophan starvation is often not effective against viruses or even all infectious microbes. As a result, this AhR activation by kynurenine can lead to a situation where viruses (or certain pathogens) continue to survive and multiply even while the immune system is effectively turning off. As a result, high levels of kynurenine and low levels of tryptophan (a high kynurenine to tryptophan or KT ratio) can lead to or even be symptomatic of chronic viral or pathogenic infections or, at worse, sepsis and septic shock (PMID: 33338598 ; PMID: 21731667 ). Kynurenine and its metabolites are also known as uremic toxins (PMID: 12092667 ). Chronically high levels of uremic toxins are known to cause damage to kidneys, liver, heart and the brain. Serum albumin binds to most uremic toxins quite strongly and can act as a first line of defense against transient rises in these compounds. |
|---|
| Structure | N[C@@H](CC(=O)C1=CC=CC=C1N)C(O)=O InChI=1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)/t8-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (2S)-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid | ChEBI | | 3-Anthraniloyl-L-alanine | ChEBI | | KYNURENINE | ChEBI | | (2S)-2-Amino-4-(2-aminophenyl)-4-oxobutanoate | Generator | | (S)-alpha,2-Diamino-3-hydroxy-gamma-oxo-benzenebutanoate | HMDB | | (S)-alpha,2-Diamino-3-hydroxy-gamma-oxo-benzenebutanoic acid | HMDB | | 3-Anthraniloyl-alanine | HMDB | | 3-Anthraniloylalanine | HMDB | | alpha,2-Diamino-gamma-oxo-benzenebutanoate | HMDB | | alpha,2-Diamino-gamma-oxo-benzenebutanoic acid | HMDB | | DL-Kynurenine | HMDB | | Kynurenin | HMDB | | Quinurenine | HMDB | | L-Kynurenine | HMDB | | 3-(2-aminobenzoyl)-L-alanine | HMDB | | KYNA | HMDB |
|
|---|
| Chemical Formula | C10H12N2O3 |
|---|
| Average Molecular Weight | 208.2139 |
|---|
| Monoisotopic Molecular Weight | 208.08479226 |
|---|
| IUPAC Name | (2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid |
|---|
| Traditional Name | L-kynurenine |
|---|
| CAS Registry Number | 2922-83-0 |
|---|
| SMILES | N[C@@H](CC(=O)C1=CC=CC=C1N)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)/t8-/m0/s1 |
|---|
| InChI Key | YGPSJZOEDVAXAB-QMMMGPOBSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Carbonyl compounds |
|---|
| Direct Parent | Alkyl-phenylketones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alkyl-phenylketone
- Butyrophenone
- Alpha-amino acid
- Alpha-amino acid or derivatives
- L-alpha-amino acid
- Benzoyl
- Gamma-keto acid
- Aniline or substituted anilines
- Aryl alkyl ketone
- Monocyclic benzene moiety
- Beta-aminoketone
- Keto acid
- Benzenoid
- Vinylogous amide
- Amino acid
- Amino acid or derivatives
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Primary aliphatic amine
- Amine
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxide
- Organic nitrogen compound
- Organonitrogen compound
- Primary amine
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 191 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.0 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.0126 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 7.4 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 244.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 570.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 262.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 67.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 165.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 62.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 265.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 279.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 657.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 622.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 102.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 765.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 184.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 199.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 472.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 387.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 294.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| L-Kynurenine,1TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N | 2063.8 | Semi standard non polar | 33892256 | | L-Kynurenine,1TMS,isomer #2 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O | 2111.3 | Semi standard non polar | 33892256 | | L-Kynurenine,1TMS,isomer #3 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O | 2162.4 | Semi standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O[Si](C)(C)C | 2096.5 | Semi standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O[Si](C)(C)C | 2129.6 | Standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O[Si](C)(C)C | 2993.1 | Standard polar | 33892256 | | L-Kynurenine,2TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O[Si](C)(C)C | 2135.3 | Semi standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O[Si](C)(C)C | 2180.7 | Standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O[Si](C)(C)C | 2878.8 | Standard polar | 33892256 | | L-Kynurenine,2TMS,isomer #3 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C)C(=O)O | 2191.3 | Semi standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #3 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C)C(=O)O | 2195.0 | Standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #3 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C)C(=O)O | 2855.4 | Standard polar | 33892256 | | L-Kynurenine,2TMS,isomer #4 | C[Si](C)(C)N([C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O)[Si](C)(C)C | 2207.2 | Semi standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #4 | C[Si](C)(C)N([C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O)[Si](C)(C)C | 2264.8 | Standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #4 | C[Si](C)(C)N([C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O)[Si](C)(C)C | 3148.5 | Standard polar | 33892256 | | L-Kynurenine,2TMS,isomer #5 | C[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@H](N)C(=O)O)[Si](C)(C)C | 2124.7 | Semi standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #5 | C[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@H](N)C(=O)O)[Si](C)(C)C | 2284.3 | Standard non polar | 33892256 | | L-Kynurenine,2TMS,isomer #5 | C[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@H](N)C(=O)O)[Si](C)(C)C | 3147.7 | Standard polar | 33892256 | | L-Kynurenine,3TMS,isomer #1 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2195.7 | Semi standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #1 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2192.8 | Standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #1 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2572.7 | Standard polar | 33892256 | | L-Kynurenine,3TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N)N([Si](C)(C)C)[Si](C)(C)C | 2247.5 | Semi standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N)N([Si](C)(C)C)[Si](C)(C)C | 2262.4 | Standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N)N([Si](C)(C)C)[Si](C)(C)C | 2889.3 | Standard polar | 33892256 | | L-Kynurenine,3TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C | 2105.8 | Semi standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C | 2289.6 | Standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C | 2673.6 | Standard polar | 33892256 | | L-Kynurenine,3TMS,isomer #4 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 2156.4 | Semi standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #4 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 2300.8 | Standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #4 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 2646.9 | Standard polar | 33892256 | | L-Kynurenine,3TMS,isomer #5 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2307.0 | Semi standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #5 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2318.0 | Standard non polar | 33892256 | | L-Kynurenine,3TMS,isomer #5 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2707.2 | Standard polar | 33892256 | | L-Kynurenine,4TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2189.6 | Semi standard non polar | 33892256 | | L-Kynurenine,4TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2286.1 | Standard non polar | 33892256 | | L-Kynurenine,4TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2395.1 | Standard polar | 33892256 | | L-Kynurenine,4TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2377.8 | Semi standard non polar | 33892256 | | L-Kynurenine,4TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2312.8 | Standard non polar | 33892256 | | L-Kynurenine,4TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2514.6 | Standard polar | 33892256 | | L-Kynurenine,4TMS,isomer #3 | C[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2332.8 | Semi standard non polar | 33892256 | | L-Kynurenine,4TMS,isomer #3 | C[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2423.3 | Standard non polar | 33892256 | | L-Kynurenine,4TMS,isomer #3 | C[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2507.8 | Standard polar | 33892256 | | L-Kynurenine,5TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2408.2 | Semi standard non polar | 33892256 | | L-Kynurenine,5TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2406.6 | Standard non polar | 33892256 | | L-Kynurenine,5TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C)[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2335.5 | Standard polar | 33892256 | | L-Kynurenine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N | 2334.7 | Semi standard non polar | 33892256 | | L-Kynurenine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O | 2350.9 | Semi standard non polar | 33892256 | | L-Kynurenine,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O | 2406.2 | Semi standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O[Si](C)(C)C(C)(C)C | 2574.2 | Semi standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O[Si](C)(C)C(C)(C)C | 2586.3 | Standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O[Si](C)(C)C(C)(C)C | 3063.7 | Standard polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O[Si](C)(C)C(C)(C)C | 2599.4 | Semi standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O[Si](C)(C)C(C)(C)C | 2659.4 | Standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N)C(=O)O[Si](C)(C)C(C)(C)C | 3001.3 | Standard polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O | 2651.6 | Semi standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O | 2645.1 | Standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O | 2993.1 | Standard polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O)[Si](C)(C)C(C)(C)C | 2703.7 | Semi standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O)[Si](C)(C)C(C)(C)C | 2684.5 | Standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)C1=CC=CC=C1N)C(=O)O)[Si](C)(C)C(C)(C)C | 3130.1 | Standard polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@H](N)C(=O)O)[Si](C)(C)C(C)(C)C | 2613.2 | Semi standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@H](N)C(=O)O)[Si](C)(C)C(C)(C)C | 2665.1 | Standard non polar | 33892256 | | L-Kynurenine,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@H](N)C(=O)O)[Si](C)(C)C(C)(C)C | 3142.6 | Standard polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2840.4 | Semi standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2826.9 | Standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2896.3 | Standard polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2913.4 | Semi standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2889.5 | Standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3042.5 | Standard polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2774.4 | Semi standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2879.0 | Standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2919.4 | Standard polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2831.6 | Semi standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2875.4 | Standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2916.0 | Standard polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3000.2 | Semi standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2899.7 | Standard non polar | 33892256 | | L-Kynurenine,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2960.0 | Standard polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 3011.5 | Semi standard non polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 3022.1 | Standard non polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2816.4 | Standard polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3208.3 | Semi standard non polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3061.9 | Standard non polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC=C1C(=O)C[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2902.5 | Standard polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3215.5 | Semi standard non polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3119.2 | Standard non polar | 33892256 | | L-Kynurenine,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=CC=CC=C1C(=O)C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2846.8 | Standard polar | 33892256 | | L-Kynurenine,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3431.7 | Semi standard non polar | 33892256 | | L-Kynurenine,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3265.5 | Standard non polar | 33892256 | | L-Kynurenine,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CC(=O)C1=CC=CC=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2816.2 | Standard polar | 33892256 |
|
|---|
| Disease References | | Schizophrenia |
|---|
- Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T: Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014 Jul 8;9(7):e101652. doi: 10.1371/journal.pone.0101652. eCollection 2014. [PubMed:25004141 ]
| | Nicotinamide Adenine Dinucleotide Deficiency |
|---|
- Shi H, Enriquez A, Rapadas M, Martin EMMA, Wang R, Moreau J, Lim CK, Szot JO, Ip E, Hughes JN, Sugimoto K, Humphreys DT, McInerney-Leo AM, Leo PJ, Maghzal GJ, Halliday J, Smith J, Colley A, Mark PR, Collins F, Sillence DO, Winlaw DS, Ho JWK, Guillemin GJ, Brown MA, Kikuchi K, Thomas PQ, Stocker R, Giannoulatou E, Chapman G, Duncan EL, Sparrow DB, Dunwoodie SL: NAD Deficiency, Congenital Malformations, and Niacin Supplementation. N Engl J Med. 2017 Aug 10;377(6):544-552. doi: 10.1056/NEJMoa1616361. [PubMed:28792876 ]
| | Sepsis |
|---|
- Ferrario M, Cambiaghi A, Brunelli L, Giordano S, Caironi P, Guatteri L, Raimondi F, Gattinoni L, Latini R, Masson S, Ristagno G, Pastorelli R: Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach. Sci Rep. 2016 Feb 5;6:20391. doi: 10.1038/srep20391. [PubMed:26847922 ]
| | Hydrocephalus |
|---|
- Heyes MP, Saito K, Milstien S, Schiff SJ: Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995 Nov;133(1-2):112-8. [PubMed:8583213 ]
| | Intraventricular hemorrhage |
|---|
- Heyes MP, Saito K, Milstien S, Schiff SJ: Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995 Nov;133(1-2):112-8. [PubMed:8583213 ]
| | CNS tumors |
|---|
- Heyes MP, Saito K, Milstien S, Schiff SJ: Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995 Nov;133(1-2):112-8. [PubMed:8583213 ]
| | CNS infections |
|---|
- Heyes MP, Saito K, Milstien S, Schiff SJ: Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995 Nov;133(1-2):112-8. [PubMed:8583213 ]
| | Crohn's disease |
|---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| | Ulcerative colitis |
|---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| | Eosinophilic esophagitis |
|---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
| | Tryptophanuria with dwarfism |
|---|
- TADA K, ITO H, WADA Y, ARAKAWA T: CONGENITAL TRYPTOPHANURIA WITH DWARFISM ("H" DISEASE-LIKE CLINICAL FEATURES WITHOUT INDICANURIA AND GENERALIZED AMINOACIDURIA):--A PROBABLY NEW INBORN ERROR OF TRYPTOPHAN METABOLISM. Tohoku J Exp Med. 1963 Jul 25;80:118-34. [PubMed:14055140 ]
|
|
|---|
| General References | - Medana IM, Day NP, Salahifar-Sabet H, Stocker R, Smythe G, Bwanaisa L, Njobvu A, Kayira K, Turner GD, Taylor TE, Hunt NH: Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J Infect Dis. 2003 Sep 15;188(6):844-9. Epub 2003 Sep 9. [PubMed:12964115 ]
- Widner B, Sepp N, Kowald E, Ortner U, Wirleitner B, Fritsch P, Baier-Bitterlich G, Fuchs D: Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology. 2000 Apr;201(5):621-30. [PubMed:10834318 ]
- Widner B, Sepp N, Kowald E, Kind S, Schmuth M, Fuchs D: Degradation of tryptophan in patients with systemic lupus erythematosus. Adv Exp Med Biol. 1999;467:571-7. [PubMed:10721102 ]
- Joseph MH: Determination of kynurenine by a simple gas-liquid chromatographic method applicable to urine, plasma, brain and cerebrospinal fluid. J Chromatogr. 1978 Jul 1;146(1):33-41. [PubMed:670356 ]
- Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP: Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J. 1998 Jul;12(10):881-96. [PubMed:9657528 ]
- Fujigaki S, Saito K, Takemura M, Fujii H, Wada H, Noma A, Seishima M: Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. Arch Biochem Biophys. 1998 Oct 15;358(2):329-35. [PubMed:9784247 ]
- Widner B, Werner ER, Schennach H, Fuchs D: An HPLC method to determine tryptophan and kynurenine in serum simultaneously. Adv Exp Med Biol. 1999;467:827-32. [PubMed:10721136 ]
- Saito K, Fujigaki S, Heyes MP, Shibata K, Takemura M, Fujii H, Wada H, Noma A, Seishima M: Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am J Physiol Renal Physiol. 2000 Sep;279(3):F565-72. [PubMed:10966936 ]
- Heyes MP, Saito K, Milstien S, Schiff SJ: Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995 Nov;133(1-2):112-8. [PubMed:8583213 ]
- Martinsons A, Rudzite V, Groma V, Bratslavska O, Widner B, Fuchs D: Kynurenine and neopterin in chronic glomerulonephritis. Adv Exp Med Biol. 1999;467:579-86. [PubMed:10721103 ]
- Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al.: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992 Oct;115 ( Pt 5):1249-73. [PubMed:1422788 ]
- Moroni F, Carpenedo R, Chiarugi A: Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system. Adv Exp Med Biol. 1996;398:203-10. [PubMed:8906267 ]
- Calandra P: Research on tryptophan metabolites "via kynurenine" in epidermis of man and mouse. Acta Vitaminol Enzymol. 1975;29(1-6):158-60. [PubMed:1244085 ]
- Manuelpillai U, Nicholls T, Wallace EM, Phillips DJ, Guillemin G, Walker D: Increased mRNA expression of kynurenine pathway enzymes in human placentae exposed to bacterial endotoxin. Adv Exp Med Biol. 2003;527:85-9. [PubMed:15206719 ]
- Greengard O: Relationship between urinary excretion of kynurenine and liver tryptophan oxygenase activity. Am J Clin Nutr. 1971 Jun;24(6):709-11. [PubMed:5581008 ]
- Heinmets F: Computer simulation and analysis of tryptophan metabolism via kynurenine pathway in liver. Comput Biol Med. 1974 Sep;1(4):323-36. [PubMed:4600391 ]
- Okuno E, Nakamura M, Schwarcz R: Two kynurenine aminotransferases in human brain. Brain Res. 1991 Mar 1;542(2):307-12. [PubMed:2029638 ]
- Altman K, Greengard O: Correlation of kynurenine excretion with liver tryptophan pyrrolase levels in disease and after hydrocortisone induction. J Clin Invest. 1966 Oct;45(10):1527-34. [PubMed:5925511 ]
- Pearson SJ, Meldrum A, Reynolds GP: An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. J Neural Transm Gen Sect. 1995;102(1):67-73. [PubMed:8785025 ]
- Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L: Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci. 2005 Dec 15;239(1):31-5. Epub 2005 Aug 15. [PubMed:16099471 ]
- Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W: Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol. 2001;33(2):399-404. [PubMed:12092667 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
- Mehraj V, Routy JP: Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests. Int J Tryptophan Res. 2015 Aug 4;8:41-8. doi: 10.4137/IJTR.S26862. eCollection 2015. [PubMed:26309411 ]
- Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca A, Pomes LM, De Luca O, Gentile G, Casolla B, Curto M, Salerno G, Schillizzi S, Torre MS, Santino I, Rocco M, Marchetti P, Aceti A, Ricci A, Bonfini R, Nicoletti F, Simmaco M, Borro M: Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. Biochim Biophys Acta Mol Basis Dis. 2021 Mar 1;1867(3):166042. doi: 10.1016/j.bbadis.2020.166042. Epub 2020 Dec 16. [PubMed:33338598 ]
- Darcy CJ, Davis JS, Woodberry T, McNeil YR, Stephens DP, Yeo TW, Anstey NM: An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One. 2011;6(6):e21185. doi: 10.1371/journal.pone.0021185. Epub 2011 Jun 22. [PubMed:21731667 ]
- Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R: Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010 Mar;16(3):279-85. doi: 10.1038/nm.2092. Epub 2010 Feb 28. [PubMed:20190767 ]
- Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T: Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19961-6. doi: 10.1073/pnas.1014465107. Epub 2010 Nov 1. [PubMed:21041655 ]
- Bartoli F, Misiak B, Callovini T, Cavaleri D, Cioni RM, Crocamo C, Savitz JB, Carra G: The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites. Mol Psychiatry. 2021 Jul;26(7):3419-3429. doi: 10.1038/s41380-020-00913-1. Epub 2020 Oct 19. [PubMed:33077852 ]
- Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK, Schwarcz R: Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011 Jul;68(7):665-74. doi: 10.1001/archgenpsychiatry.2011.71. [PubMed:21727251 ]
- Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM: Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005 Aug;31(4):395-404. doi: 10.1111/j.1365-2990.2005.00655.x. [PubMed:16008823 ]
- Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, Trusinskis K, Fuchs D: Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 2003 Jul;33(7):550-4. doi: 10.1046/j.1365-2362.2003.01186.x. [PubMed:12814390 ]
- Gulaj E, Pawlak K, Bien B, Pawlak D: Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci. 2010;55(2):204-11. doi: 10.2478/v10039-010-0023-6. [PubMed:20639188 ]
|
|---|